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Abstract
Robotic surgery for renal cell carcinoma (RCC) is increasingly adopted for cT1 disease, but its utilization for cT2 disease
remains unexplored. We aimed to characterize the trend in robotic approach for cT2 RCC. The National Cancer Database
was queried for patients who were diagnosed with cT2N0M0 RCC from 2010 to 2016 and underwent subsequent radical
(RN) or partial (PN) nephrectomy. Analysis of treatment trends was performed and logistic regression (LR) undertaken for
predictors of surgical approach. 21,258 patients met inclusion criteria for analysis; 1698 (8%) underwent a PN and 19,560
(92%) underwent RN. Use of robotics in PN increased 346% (12.3–42.6%) and 351% (6.2–21.8%) for RN during the studied
time period. Robotic PN or RN was associated with shorter hospital stay compared to non-robotic approaches (p < 0.001).
Academic institutions were more likely to perform a robotic procedure and the uninsured were less likely to receive robotic
approach. There was no association between age, sex, race, or income and surgical approach. On LR, robotic approach was
independently associated with academic institutions and a more recent year of diagnosis. There was no significant difference in the rate of positive margins, 30-day readmission, or 30/90-day mortality between approaches. Robotic PN and RN is
becoming an increasingly popular approach in the treatment of cT2 RCC. Utilization of robotics is associated with academic
institutions and results in a shorter hospital stay without significant differences rate of positive margins, readmission rates,
or 30/90-day mortality.
Keywords Kidney cancer · Robotic · Minimally invasive · Clinical practice pattern

Introduction
Partial nephrectomy (PN) and radical nephrectomy (RN) are
well established as the two definitive treatments of choice
for renal cell carcinoma (RCC) [1]. Generally, PN is favored
for small renal masses (cT1), whereas RN is favored for
larger, more complex tumors (cT2–T4); however, the use
of PN has been applied in select patients with larger cT2
tumors [2]. Additionally, the decision of treatment approach
(open vs. laparoscopic vs. robotic) must account for the characteristics of the renal mass, along with the surgeon and
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patient preference. Robotic surgery was initially utilized for
cT1 tumors that were minimally complex; however, with
improvements in robotic technology and increased surgical
training, a robotic approach has been shown to be a viable
option to cT2 disease [3–5].
Institutional studies and systematic reviews have shown
the expanding utilization of robotic surgery in the treatment of RCC; however, these studies failed to distinguish
approach based on clinical T stage which often contributes
to decision making when choosing approach. [6–9] To further elucidate the advantages to robotic surgery, we analyzed the nation-wide trend in surgical approach for treating
cT2 RCC focusing on surgical and oncologic outcomes. We
hypothesized that the landscape of cT2 RCC treatment is
shifting in favor of robotic surgery.
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Materials and methods

Statistical analysis and outcome measures

Data source

Our primary aim was the trend in treatment approach
(robotic vs. non-robotic) used for cT2 RCC resection.
Non-robotic approach was defined as open, laparoscopic
or converted open surgical approach. Secondary outcomes
include trend of treatment type (RN vs PN), rates of positive
margins and 30-day readmission between robotic and nonrobotic approaches. Student’s T test was performed for continuous variables. Fischer’s exact or Pearson Chi-square test
was used for categorical variables. Using factors that were
deemed clinically significant, we performed multivariable
logistic regression to identify risk factors associated with
outcomes. We utilized SPSS v26 (New York, United States)
for all analyses, with p value of < 0.05 denoting statistical
significance.

Data for this analysis were derived from the Commission
on Cancer’s National Cancer Data Base (NCDB) Participant User File for RCC from 2010 to 2016. The NCDB
is a national cancer outcomes dataset that includes input
from over 1500 Commission on Cancer-accredited centers
in the United States. These data include all cancer patients
treated at participating Commission on Cancer-accredited
institutions and are estimated to capture over 70% of new
cancer cases in the United States [10]. Standardized coding
definitions are utilized, and the data are freely available
to participating institutions after application for projects
are accepted by the NCDB. The data used in the study are
derived from a de-identified NCDB file. The American
College of Surgeons and the Commission on Cancer have
not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn
from these data by the investigator.

Study population
The National Cancer Database (NCDB) was queried for
patients who were diagnosed with cT2 RCC from 2010
to 2016, including site-specific histology codes for clear
cell, papillary, sarcomatoid, chromophobe and renal cell
carcinoma not otherwise specified, and underwent subsequent RN or PN. PN was defined as partial or subtotal
nephrectomy using site-specific surgery code 30. RN was
defined as complete/total/simple nephrectomy for kidney
parenchyma and radical nephrectomy using site-specific
surgery codes 40 and 50. This study period was chosen,
as the NCDB participant user file began noting information regarding surgical approach (robotic, laparoscopic,
open, open conversion) in 2010. Patients were excluded
if they had clinically nodal positive disease or clinically
metastatic positive disease. 21,258 patients age ≥ 18 were
identified and met inclusion criteria.
Patient demographic variables included age, sex, race,
Charlson comorbidity index, income status, facility type,
and insurance status. Disease and operative outcomes
included surgical approach, length of hospital stay, clinical tumor stage, pathological tumor stage, margin status,
length of follow-up, 30-day readmission, and 30-day mortality. Tumor size was not included in our analysis as the
NCDB only records up to 9.9 cm. Therefore, measurements of all cT2b renal masses (> 10 cm) would not have
been specified in the analysis.
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Results
Patient demographics and tumor characteristics
In total, 21,258 subjects underwent surgical treatment for
clinical grade T2 renal masses. Tables 1 and 2 represent
patients undergoing PN and RN, respectively, who are then
further divided based on surgical approach. There were 1698
PN patients with 526 robotic and 1172 non-robotic approach.
In Table 2, there were 19,560 in the RN cohort with 2808
undergoing a robotic and 16,752 a non-robotic approach.
There were no significant differences in the demographics
between the two groups in the PN population. Meanwhile,
in the RN population, patients undergoing robotic approach
were less likely to be uninsured and more likely to receive
their care in an academic facility (p < 0.001). Clinical stage
of cT2a portended a robotic approach instead of an open/
laparoscopic approach in both the PN (65.8% vs 59.9%) and
RN (58.3% vs 50.5%) cohort.

Perioperative complications and survival outcomes
Tables 3 and 4 compare perioperative and survival outcomes
of robotic surgery to non-robotic surgery for both PN and
RN. In Table 3, patients who underwent a robotic PN had
shorter hospital stays compared to non-robotic approaches
(3.3 days versus 5.2 days, p < 0.001). When comparing the
rates of pathologic upstaging, rates of positive margins,
30-day readmission rates, and 30-day mortality, no difference between the two groups was observed. Similar trends
were shown in Table 4, when comparing a robotic approach
to non-robotic approaches for RN. The robotic RN cohort
had shorter hospital stays (3 days vs 4.2 days, p < 0.001)
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Table 1  Patient demographics and clinical tumor characteristics—
partial nephrectomy
Variable

All PN
(n = 1698)

Open/Lap PN Robotic PN Sig
(n = 1172)
(n = 526)

Mean age
Sex
Male
Female
Race
White
Black
Other
Charlson
0
1
2
3+
Income status
< $38,000
$38,000–
47,999
$48,000–
62,999
$63,000 +
Facility type
Comm cancer
Comp comm
cancer
Academic
Integrated
network
Uninsured
cT stage
cT2a
cT2b
cT2x
Approach
Open
Laparoscopic
Converted
open
Robotic

60.5 ± 12.1

60.6 ± 12.1

60.1 ± 12.2

1209 (71.2%) 836 (71.3%)
489 (28.8%) 336 (28.7%)

373 (70.9%)
153 (29.1%)

1359 (80.0%) 928 (79.2%)
263 (15.5%) 186 (15.9%)
76 (4.5%)
58 (4.9%)

431 (81.9%)
77 (14.6%)
18 (3.4%)

1125 (66.3%)
388 (22.9%)
117 (6.9%)
68 (4.0%)

788 (67.2%)
255 (21.8%)
83 (7.1%)
46 (3.9%)

337 (64.1%)
133 (25.3%)
34 (6.5%)
22 (4.2%)

288 (17.0%)
411 (24.2%)

205 (17.5%)
284 (24.3%)

83 (15.8%)
127 (24.2%)

411 (24.2%)

266 (22.7%)

145 (27.6%)

586 (34.6%)

416 (35.5%)

170 (32.4%)

66 (4.1%)
417 (25.9%)

49 (4.4%)
280 (25.1%)

17 (3.4%)
137 (27.7%)

928 (57.6%)
201 (12.5%)

658 (58.9%)
130 (11.6%)

270 (54.5%)
71 (14.3%)

42 (2.5%)

30 (2.6%)

12 (2.3%)

1048 (61.7%) 702 (59.9%)
251 (14.8%) 192 (16.4%)
399 (23.5%) 278 (23.7%)

346 (65.8%)
59 (11.2%)
121 (23.0%)

891 (52.5%)
238 (14.0%)
43 (2.5%)

891 (76.0%)
238 (20.3%)
43 (3.7%)

N/A
N/A
N/A

526 (31.0%)

N/A

526 (100%)

0.417
0.862

0.274

0.425

24% in the treatment of cT2 RCC. Utilization of robotic
surgery increased by 346% (from 12.3 to 42.6%) for PN and
351% (from 6.2 to 21.8%) for RN.

Multivariable analysis: robotic approach
Table 5 is a logistic regression for robotic approach. For
RN, surgery at an academic hospital or a more recent year
of diagnosis were positively predictive of robotic approach
(p < 0.001). Black race, being uninsured and cT2b disease
were negatively predictive of robotic surgery (p < 0.05). As
for PN, a more recent year of diagnosis was also positively
predictive of robotic utilization, while cT2b disease was
negatively predictive of a robotic approach (p < 0.05).

Discussion
0.154

0.186

0.863
0.013

N/A

without significant differences in pathologic upstaging, rates
of positive margins, 30-day readmission rates, or 30-day
mortality.

Surgical approach over time
Figure 1 outlines the nation-wide trend of robotic approach
in cT2 RCC. Over the study period of 2010–2016, the overall rate of robotic surgery increased from about 6% to nearly

In this population-based retrospective review of various surgical approaches to cT2 RCC, we found a drastic increase in
the use of robotics from 2010 to 2016. A robotic approach
was undertaken in 42.6% of PN in 2016, up from 12.3%
in 2010. RN saw a similarly large increase in utilization
of robotics from 6.2 to 21.8%. Robotic approach was not
associated with adverse clinical and oncologic outcomes,
such as 30-day readmission rates, 30-day mortality, positive
margins or rates of pathological upstaging when compared
to non-robotic approaches. Instead, patients undergoing
robotic surgery experienced a shorter hospital stay. On multivariate analysis, an academic hospital positively predicts
the use robotics whereas uninsured and cT2b disease are
negatively predictive. Taken together, this data suggests that
robotic surgery in the treatment of cT2 disease is becoming
an increasingly popular surgical option that provides similar outcomes to other surgical approaches in well-selected
patients.
Our findings support current literature with respect to the
rising rates of robotic surgery used for RCC. In an NCDB
analysis by Alameddine et al., rates of robotic-assisted PN
(RAPN) for cT1 disease increased to 63% in 2013 from 41%
in 2010 [11]. Jabaji et al. found a similar increase in RAPN
at their institution from 2011 to 2014 [12]. For RN, Jeong
et al. reported that a robotic approach comprised 27% of
RN in 2015 up from just 1.5% in 2003 [13]. However, to
our knowledge, our study is the first to establish the uptrend
in robotic surgery specific to larger and surgically complex
cT2 disease. The driving force behind this finding is not
clear and likely multifactorial. One potential explanation is
increased training on the robotic platform during training,
leading to its application with many urologic procedures.
Robot-assisted radical prostatectomy quickly took over open
prostatectomy during the early 2000s, comprising 85% of
cases in 2013, likely even a higher percentage now [14].
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Table 2  Patient demographics
and clinical tumor
characteristics—radical
nephrectomy

Variable

All RN
(n = 19,560)

Open/Lap RN
(n = 16,752)

Robotic RN
(n = 2808)

Sig

Mean age
Sex
Male
Female
Race
White
Black
Other
Charlson
0
1
2
3+
Income status
< $38,000
$38,000–47,999
$48,000–62,999
$63,000 +
Facility type
Comm cancer
Comp comm cancer
Academic
Integrated network
Uninsured
cT stage
cT2a
cT2b
cT2x
Approach
Open
Laparoscopic
Converted open
Robotic

60.9 ± 12.2

60.8 ± 12.2

61.1 ± 12.0

12,815 (65.5%)
6745 (34.5%)

10,954 (65.4%)
5798 (34.6%)

1861 (66.3%)
947 (33.7%)

0.231
0.368

16,527 (84.5%)
2154 (11.0%)
879 (4.5%)

14,131 (84.4%)
1885 (11.3%)
736 (4.4%)

2396 (85.3%)
269 (9.6%)
143 (5.1%)

13,682 (69.9%)
4115 (21.0%)
1190 (6.1%)
573 (2.9%)

11,735 (70.1%)
3523 (21.0%)
1025 (6.1%)
469 (2.8%)

1947 (69.3%)
592 (21.1%)
165 (5.9%)
104 (3.7%)

3437 (17.6%)
4643 (23.8%)
5353 (27.4%)
6088 (31.2%)

2950 (17.6%)
4001 (23.9%)
4606 (27.6%)
5159 (30.9%)

487 (17.4%)
642 (22.9%)
747 (26.6%)
929 (33.1%)

1386 (7.4%)
7633 (40.9%)
6997 (37.5%)
2655 (14.2%)
804 (4.1%)

1256 (7.9%)
6630 (41.5%)
5902 (37.0%)
2182 (13.7%)
728 (4.3%)

130 (4.8%)
1003 (37.1%)
1095 (40.5%)
473 (17.5%)
76 (2.7%)

10,093 (51.6%)
5498 (28.1%)
3969 (20.3%)

8457 (50.5%)
4929 (29.4%)
3366 (20.1%)

1636 (58.3%)
569 (20.3%)
603 (21.5%)

8710 (44.5%)
7410 (37.9%)
632 (3.2%)
2808 (14.4%)

8710 (52.0%)
7410 (44.2%)
632 (3.8%)
N/A

N/A
N/A
N/A
2808 (100%)

Alternatively, although an oncological and survival benefit
to robotic nephrectomy compared to non-robotic approaches
has not been proven, there is increasing evidence suggesting
superior perioperative outcomes, such as lower estimated
blood loss, fewer postoperative complications, and shorter
hospital stays [6, 8, 9]. These benefits are confirmed in our
own analysis, suggesting a decreased length of stay for
robotic surgery, even in the setting of larger renal masses.
Thus, while long-term outcomes are not fully elucidated, the
short-term perioperative benefits may sway surgeon preference towards a robotic approach for cT2 disease.
A shorter hospital stay experienced after robotic nephrectomy has been previously reported, but its significance
requires further investigation [8, 15]. Cost analyses regarding surgical approach are not in unanimous agreement. In a
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0.011

0.068

0.117

< 0.001

< 0.001
< 0.001

N/A

nation-wide review by Jeong et al. and Yang et al. from 2003
to 2015 and 2009 to 2011 respectively, robotic-assisted RN
(RARN) was associated with a significantly higher hospital and total cost compared to laparoscopic-assisted radical
nephrectomy (LARN) [13, 16]. On an institutional level,
Helmers et al. report a higher cost trend in RARN compared
to LARN, but lacked statistical significance [17]. In contrast,
Buse et al. report a cost benefit to RAPN relative to open PN
at select high-volume centers, as the increased supply and
maintenance of a robotic platform was offset by the shorter
hospital stay and fewer perioperative complications [18].
Moreover, as reported by Bahler et al., the cost of RAPN
is downtrending and demonstrated a cost benefit to open
nephrectomy in 2012 despite being $1,464 more expensive
three years prior [19]. Altogether, it appears there is no

Journal of Robotic Surgery
Table 3  Perioperative and
survival outcomes—partial

Table 4  Perioperative and
survival outcomes—radical

Variable

All PN
(n = 1698)

Open/Lap PN
(n = 1172)

Robotic PN
(n = 526)

Hospital stay (days)
pT stage
pT1
pT2
pT3
pT4
Upstaging
Margin status
Negative
Positive
Unknown or N/A
Complications
30-Day readmission
Death within 30 days

4.6 ± 6.3

5.2 ± 7.0

3.3 ± 4.2

325 (19.1%)
1131 (66.6%)
240 (14.1%)
2 (0.1%)
242 (14.2%)

196 (16.7%)
810 (69.1%)
164 (14.0%)
2 (0.2%)
166 (14.2%)

129 (24.5%)
321 (61.0%)
76 (14.4%)
0 (0%)
76 (14.4%)

1560 (91.9%)
119 (7.0%)
19 (1.1%)

1082 (92.3%)
78 (6.7%)
12 (1.0%)

478 (90.0%)
41 (7.8%)
7 (1.3%)

49 (2.9%)
6 (0.4%)

32 (2.7%)
4 (0.3%)

17 (3.2%)
2 (0.4%)

Variable

All RN
(n = 19,560)

Open/Lap RN
(n = 16,752)

Robotic RN
(n = 2808)

Hospital stay (days)
pT stage
pT1
pT2
pT3
pT4
Upstaging
Margin status
Negative
Positive
Unknown or N/A
Complications
30-Day readmission
Death within 30 days

4.0 ± 3.7

4.2 ± 3.8

3.0 ± 2.8

1902 (9.7%)
11,839 (60.5%)
5663 (29.0%)
155 (0.8%)
5818 (29.8%)

1534 (9.2%)
10,201 (60.9%)
4880 (29.1%)
137 (0.8%)
5017 (29.9%)

369 (13.1%)
1638 (58.3%)
783 (27.9%)
18 (0.6%)
801 (28.5%)

18,973 (97.0%)
470 (2.4%)
117 (0.6%)

16,237 (96.9%)
411 (2.5%)
104 (0.6%)

2736 (97.4%)
59 (2.1%)
13 (0.5%)

476 (2.4%)
125 (0.6%)

414 (2.5%)
111 (0.7%)

62 (2.2%)
14 (0.5%)

Roboc Approach Over Time

50.0%

Roboc Approach Rate

45.0%
40.0%
35.0%
30.0%
25.0%

PN or RN

20.0%

PN

15.0%

RN

10.0%
5.0%
0.0%

2010

2011

2012

2013

2014

Year of Surgery

Fig. 1  Robotic utilization over time

2015

2016

Sig
< 0.001
0.001

0.881
0.588

0.638
0.901

Sig
< 0.001
< 0.001

0.133
0.315

0.426
0.369

unanimous cost benefit to favor a given approach. Rather,
a cost-effective approach is one that takes into account the
specific tumor characteristics, a surgeon’s preference, the
experience of the treatment center, and the always evolving
paradigm of surgical technology.
Our multivariate analysis is in agreement with prior
work revealing the discrepancies in the distribution of
robotic surgery application; namely black race and being
uninsured negatively predicts a robotic approach to cT1
and cT2 RCC nephrectomy [11, 20]. It is widely known
that minorities and patients with a low socioeconomic
status have unequal access to health care and are more
likely to have their surgery at low-volume centers [21, 22].
Considering we found academic hospitals to be predicative
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Table 5  Logistic regression for
robotic approach

Variable

Age
Male sex
Race (white ref)
Black
Other
Charlson (0 ref)
1
2
3+
Income (< $38,000 ref)
$38,000–47,999
$48,000–62,999
$63,000 +
Academic
Uninsured
Year of diagnosis
cT2 stage (cT2x ref)
cT2a
cT2b

Radical

Partial

OR

OR

95% CI low 95%CI high Sig

95% CI low 95% CI high Sig

.999 .996
1.033 .948

1.003
1.125

.694 .995 .986
.463 1.012 .799

1.003
1.282

.228
.921

.855 .743
1.096 .908

.984
1.322

.029 .967
.340 .695

.709
.397

1.319
1.216

.832
.203

1.054 .952
.952 .799
1.129 .902

1.167
1.135
1.411

.310 1.290 .999
.584 .960 .621
.289 .879 .505

1.665
1.483
1.530

.051
.853
.647

.943
.950
1.036
1.175
.641
1.248

.827
.836
.915
1.080
.502
1.221

1.074
1.079
1.172
1.278
.820
1.276

.377
.428
.578
.000
.000
.000

1.639
1.887
1.503
1.045
1.991
1.377

.408
.098
.661
.118
.963
.000

.943
.563

.850
.497

1.046
.638

.270 1.054 .812
.000 .662 .456

1.367
.961

.693
.030

1.158
1.337
1.077
.842
.984
1.297

.818
.948
.772
.679
.486
1.222

Bold data indicates p < 0.05
OR odds ratio, CI confidence interval, sig significance, ref reference

of a robotic approach, there is a risk of a treatment gap
for at-risk patient group and a lack of access to this novel
approach for cT2 disease. Given the comparable outcomes
between surgical approaches, expanding robotic utilization
to low-volume centers and improving access to health care
for minority and uninsured patients may increase access
for appropriate, cost-effective surgical decision making for
these populations.
When subclassifying cT2 RCC into cT2a and cT2b,
we report cT2b disease to be negatively predictive of both
RAPN and RARN. While this suggests tumor size may be
an important barrier to robotic surgery, the tumor staging
used in this study is likely a surrogate of the relative tumor
complexity. In general, larger tumors tend to be considered
more complex, but size alone does not adequately characterize the mass. Ideally, imaging review with calculation of
a RENAL nephrometry score (RNS) would be performed,
but this is not available within the NCDB database [23]. The
RNS considers not only the tumor size, but also its nearness
to the collecting system, vessels and overall location within
the kidney, giving a much better approximation of tumor
complexity. RNS is widely used and prior work has found
RNS to be predictive of tumor grade and various perioperative and overall outcome measures [24–26]. Therefore,
future cohorts exploring detailed radiographic morphometrics, such as RNS, in the context of surgical approach, may
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provide a more comprehensive understanding of the variables driving the widespread increased usage of robotics.
An important limitation to our retrospective study design
is we cannot readily determine the reason for the trends
observed. We drew from other literature and clinical experience, but without the aforementioned decisional variables,
namely patient’s surgical preference, the surgeon preference,
or the specific tumor characteristics, it is merely hypothesis
generation. Although the NCDB data collection is a standardized process, certain data are unable to be obtained due to
insufficient documentation. For example, nearly 21% of the
study population did not have tumor staging documented,
and thus had to be excluded in the multivariate analysis.
Lastly, incorrect coding and data entry errors in the NCDB
are a possible confounding factor, but we do not believe
this played a large role in our study. Overall, we believe our
analysis sheds light on and validates the recent shift toward
robotic surgery for cT2 RCC while emphasizing the inequality and limitations to its application, laying the framework
for future investigations.

Conclusion
Over our study period of 2010–2016, robotic PN and RN
was an increasingly popular approach in the treatment of
cT2 RCC. Utilization of robotics is associated with academic

Journal of Robotic Surgery

institutions and results in a shorter hospital stay without significant differences in the rate of positive margins, readmission rates, or 30/90 day mortality.
Author contributions TS, FD, SJR, and ZH contributed to the study
conception and design. Data analysis was performed by ZH. The first
draft of the manuscript was written by TS, and all authors commented
on the final version of the manuscript. All authors read and approved
the final manuscript.
Funding Not applicable.
Availability of data and material Freely available to participating
institutions.
Code availability Not applicable.

Declarations
Conflict of interest Not applicable.
Ethical approval Not required due to nature of data collection.

References
1. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani
S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA
et al (2019) European Association of Urology Guidelines on Renal
Cell Carcinoma: the 2019 update. Eur Urol 75(5):799–810
2. Li J, Zhang Y, Teng Z, Han Z (2019) Partial nephrectomy versus
radical nephrectomy for cT2 or greater renal tumors: a systematic
review and meta-analysis. Minerva Urol Nefrol 71(5):435–444
3. Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, Eun D, Perdona S, Porter J, Rha KH et al (2018) Outcomes
of robot-assisted partial nephrectomy for clinical T2 renal tumors:
a multicenter analysis (ROSULA Collaborative Group). Eur Urol
74(2):226–232
4. Brandao LF, Zargar H, Autorino R, Akca O, Laydner H, Samarasekera D, Krishnan J, Haber GP, Stein RJ, Kaouk JH (2014) Robotassisted partial nephrectomy for ≥ 7 cm renal masses: a comparative
outcome analysis. Urology 84(3):602–608
5. Malkoc E, Ramirez D, Kara O, Maurice MJ, Nelson RJ, Caputo
PA, Kaouk JH (2017) Robotic and open partial nephrectomy for
localized renal tumors larger than 7 cm: a single-center experience.
World J Urol 35(5):781–787
6. Zeuschner P, Greguletz L, Meyer I, Linxweiler J, Janssen M,
Wagenpfeil G, Wagenpfeil S, Siemer S, Stöckle M, Saar M (2021)
Open versus robot-assisted partial nephrectomy: a longitudinal comparison of 880 patients over 10 years. Int J Med Robot 17(1):1–8
7. Grivas N, Kalampokis N, Larcher A, Tyritzis S, Rha KH, Ficarra V,
Buffi N, Ploumidis A, Autorino R, Porpiglia F et al (2019) Robotassisted versus open partial nephrectomy: comparison of outcomes.
A systematic review. Minerva Urol Nefrol 71(2):113–120
8. Wu Z, Li M, Liu B, Cai C, Ye H, Lv C, Yang Q, Sheng J, Song S, Qu
L et al (2014) Robotic versus open partial nephrectomy: a systematic
review and meta-analysis. PLoS ONE 9(4):e94878
9. Xia L, Wang X, Xu T, Guzzo TJ (2017) Systematic review and metaanalysis of comparative studies reporting perioperative outcomes of
robot-assisted partial nephrectomy versus open partial nephrectomy.
J Endourol 31(9):893–909

10. Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The
National Cancer Data Base: a powerful initiative to improve cancer
care in the United States. Ann Surg Oncol 15(3):683–690
11. Alameddine M, Koru-Sengul T, Moore KJ, Miao F, Sávio LF, Nahar
B, Prakash NS, Venkatramani V, Jue JS, Punnen S et al (2019)
Trends in utilization of robotic and open partial nephrectomy for
management of cT1 renal masses. Eur Urol Focus 5(3):482–487
12. Jabaji RB, Fischer H, Kern T, Chien GW (2019) Trend of surgical
treatment of localized renal cell carcinoma. Perm J 23:18–108
13. Jeong IG, Khandwala YS, Kim JH, Han DH, Li S, Wang Y, Chang
SL, Chung BI (2017) Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and
Health Care Costs, 2003 to 2015. JAMA 318(16):1561–1568
14. Leow JJ, Chang SL, Meyer CP, Wang Y, Hanske J, Sammon JD,
Cole AP, Preston MA, Dasgupta P, Menon M et al (2016) Robotassisted versus open radical prostatectomy: a contemporary analysis
of an all-payer discharge database. Eur Urol 70(5):837–845
15. Garisto J, Bertolo R, Dagenais J, Sagalovich D, Fareed K, Fergany
A, Stein R, Kaouk J (2018) Robotic versus open partial nephrectomy
for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes. Urol Oncol 36(10):471.e471-471.
e479
16. Yang DY, Monn MF, Bahler CD, Sundaram CP (2014) Does robotic
assistance confer an economic benefit during laparoscopic radical
nephrectomy? J Urol 192(3):671–676
17. Helmers MR, Ball MW, Gorin MA, Pierorazio PM, Allaf ME (2016)
Robotic versus laparoscopic radical nephrectomy: comparative analysis and cost considerations. Can J Urol 23(5):8435–8440
18. Buse S, Hach CE, Klumpen P, Schmitz K, Mager R, Mottrie A,
Haferkamp A (2018) Cost-effectiveness analysis of robot-assisted
vs. open partial nephrectomy. Int J Med Robot 14(4):e1920
19. Bahler CD, Monn MF, Flack CK, Gramm AR, Gardner TA, Sundaram CP (2018) Assessing cost of robotic utilization in partial
nephrectomy with increasing utilization. J Endourol 32(8):710–716
20. Xia L, Talwar R, Taylor BL, Shin MH, Berger IB, Sperling CD,
Chelluri RR, Zambrano IA, Raman JD, Guzzo TJ (2019) National
trends and disparities of minimally invasive surgery for localized
renal cancer, 2010 to 2015. Urol Oncol 37(3):182.e117-182.e127
21. Liu JH, Zingmond DS, McGory ML, SooHoo NF, Ettner SL, Brook
RH, Ko CY (2006) Disparities in the utilization of high-volume
hospitals for complex surgery. JAMA 296(16):1973–1980
22. Trinh QD, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR,
Jeong W, Dabaja A, Shariat SF, Perrotte P et al (2012) Disparities
in access to care at high-volume institutions for uro-oncologic procedures. Cancer 118(18):4421–4426
23. Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score:
a comprehensive standardized system for quantitating renal tumor
size, location and depth. J Urol 182(3):844–853
24. Chen SH, Wu YP, Li XD, Lin T, Guo QY, Chen YH, Huang JB, Wei
Y, Xue XY, Zheng QS et al (2017) R.E.N.A.L. Nephrometry Score:
a preoperative risk factor predicting the fuhrman grade of clear-cell
renal carcinoma. J Cancer 8(18):3725–3732
25. Basu S, Khan IA, Das RK, Dey RK, Khan D, Agarwal V (2019)
RENAL nephrometry score: predicting perioperative outcomes following open partial nephrectomy. Urol Ann 11(2):187–192
26. Veccia A, Antonelli A, Uzzo RG, Novara G, Kutikov A, Ficarra V,
Simeone C, Mirone V, Hampton LJ, Derweesh I et al (2020) Predictive Value of Nephrometry Scores in Nephron-sparing Surgery: a
systematic review and meta-analysis. Eur Urol Focus 6(3):490–504
Publisher's Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.

13

